Comparing tyrosine kinase inhibitor treatment strategies for newly diagnosed chronic myeloid leukemia in chronic phase when imatinib loses patent exclusivity in the u.s.- a cost-effectiveness analysis
May 1, 2015, 00:00 AM
10.1016/j.jval.2015.03.1185
https://www.valueinhealthjournal.com/article/S1098-3015(15)01242-5/fulltext
Section Title :
Cancer
Section Order :
648
First Page :
A205
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01242-5&doi=10.1016/j.jval.2015.03.1185